Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Operating Expenses: 2009-2024

Historic Operating Expenses for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $613.8 million.

  • Ani Pharmaceuticals' Operating Expenses rose 13.46% to $191.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $754.9 million, marking a year-over-year increase of 38.83%. This contributed to the annual value of $613.8 million for FY2024, which is 39.55% up from last year.
  • Ani Pharmaceuticals' Operating Expenses amounted to $613.8 million in FY2024, which was up 39.55% from $439.8 million recorded in FY2023.
  • Over the past 5 years, Ani Pharmaceuticals' Operating Expenses peaked at $613.8 million during FY2024, and registered a low of $224.5 million during FY2020.
  • For the 3-year period, Ani Pharmaceuticals' Operating Expenses averaged around $468.4 million, with its median value being $439.8 million (2023).
  • As far as peak fluctuations go, Ani Pharmaceuticals' Operating Expenses dropped by 14.00% in 2021, and later skyrocketed by 39.55% in 2024.
  • Ani Pharmaceuticals' Operating Expenses (MRY) stood at $224.5 million in 2020, then increased by 14.00% to $255.9 million in 2021, then surged by 37.41% to $351.7 million in 2022, then rose by 25.07% to $439.8 million in 2023, then surged by 39.55% to $613.8 million in 2024.
  • Its last three reported values are $613.8 million in FY2024, $439.8 million for FY2023, and $351.7 million during FY2022.